HGF、c-MET及VEGF在非小细胞肺癌中的表达和意义

目的 探讨肝细胞生长因子(HGF)、肝细胞生长因子受体(c-MET)及血管内皮生长因子(VEGF)的表达与非小细胞肺癌临床病理的关系.方法 将组织标本分为原发灶组(357例)和正常对照组(68例),分别采用免疫组织化学方法检测各组标本中HGF、c-MET及VEGF的表达情况.结果 非小细胞肺癌原发灶组织和正常组织中HGF表达阳性率分别为51.26％ (183/357)和10.29％ (7/68),两组之间差异有统计学意义(P＜0.05);非小细胞肺癌原发灶组织和正常组织中c-MET表达阳性率分别为60.22％ (215/357)和14.71％(10/68),两组间差异有统计学意义(P＜0.05);非小细胞肺癌原发灶组织和正常组织中VEGF表达阳性率分别为45.38％(162/357)和11.76％(8/68),两组间差异有统计学意义(P＜0.05);HGF阳性表达率与肿瘤组织分化程度及临床分期无关(P＞0.05),c-MET及VEGF阳性表达率与肿瘤组织分化程度及临床分期相关(P＜0.05).结论 HGF和c-MET、VEGF可能共同参与了非小细胞肺癌的发生和发展,c-MET和VEGF或可作为预测非小细胞肺癌患者预后的标记物.

Expression and Significance of HGF,c-MET and VEGF in Non-small Cell Lung Cancer

Objective To explore the expression of HGF,c-MET and VEGF in non-small cell lung cancer,and their relationship with clinical pathology.Methods The tissue specimens were divided into primary tumor group(357 cases) and normal control group (68 cases),respectively using immunohistochemical method to detect each specimen expression of HGF,c-MET and VEGF.Results There was a significant difference between primary tumor group 51.26％ (183/357)] and normal control group 10.29 ％ (7/68)] by HGF protein expression in non-small cell lung cancer (P ＜ 0.05);There was significant difference between primary tumor group60.22％ (215/357)] and normal control group14.71％ (10/68)] by c-MET protein expression in nonsmall cell lung cancer (P ＜ 0.05);There was a significant difference between primary tumor group 45.38 ％ (162/357)] and normal control group 11.76％ (8/68)] by VEGF protein expression in non-small cell lung cancer(P ＜ 0.05);The positive expression rate of HGF protein had nothing to do with tumor tissue differentiation degree and the staging of tumor tissue (P ＞ 0.05),and the positive expression rate of c-MET and VEGF were associated with the differentiation degree and the staging of tumor tissue (P＜ 0.05).Conclusion The protein of HGF and c-MET and VEGF may be involved in the occurrence and development of nonsmall cell lung cancer,and c-MET and VEGF maybe used as markers for predicting the prognosis of patients with non-small cell lung cancer.